Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of elritercept versus epoetin alfa for transfusion-dependent anemia in lower-risk myelodysplastic syndromes
NL-OMON61052Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in myelodysplastic syndrome (MDS) comparing Elritercept with Epoetin alfa (2 arms). Primary endpoint: Red blood cell transfusion independence for at least 12 weeks with hemoglobin increase. Planned start May 2026; status: not yet recruiting.
02
Drugs
elriterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON61052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61052.